(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival. The 24-year, phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer — which accounts for 80-90 per cent of cases — can safely take HRT during or after their treatment.
Related Topics
OCRA Names Dmitriy Zamarin, MD, PhD, as 2026 Liz Tilberis Research Prize Winner
Dmitriy Zamarin, MD, PhD, has been awarded the 2026 Liz Tilberis Research Prize for Outstanding Early Career Investigators by Ovarian Cancer Research Alliance (OCRA). A physician-scientist whose research has explored new approaches to harnessing the immune system against ovarian cancer, Dr. Zamarin is Professor of Oncology, Section Head of Gynecologic Medical Oncology, and Co-Director of … Continued
OCRA Awards 2026 Rosalind Franklin Excellence in Ovarian Cancer Research Prize to Kenneth Nephew, PhD
Ovarian Cancer Research Alliance (OCRA) has named Kenneth Nephew, PhD, as the winner of the 2026 Rosalind Franklin Excellence in Ovarian Cancer Research Prize. For more than three decades, he has helped advance the field of ovarian cancer research through both his investigations into treatment resistance and his mentorship of others studying this disease. “Dr. … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2026 to reflect NCCN’s release of the 2026 Guidelines for Ovarian Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Ovarian Cancer, Cervical Cancer, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed … Continued